{
  "id": 150794,
  "title": "New recommendations address GLP-1 medications across women's reproductive years",
  "url": "https://urgent.news/2026/08/04/new-recommendations-address-glp-1-medications-across-womens",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-04T23:40:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-glp-medications-women-reproductive-years.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "A new international review and consensus guideline published in Obesity Reviews provides comprehensive clinical recommendations for the use of GLP-1 and other incretin-based medications across the reproductive lifespan. Developed by experts from Europe, North America, and the Middle East, the review addresses key questions related to fertility, pregnancy outcomes, breastfeeding, and postpartum health. While the available evidence does not identify an increased risk of major congenital anomalies following inadvertent early pregnancy exposure, substantial evidence gaps remain, particularly regarding long-term maternal and child outcomes. Incretin-based medications may improve fertility-related outcomes in women with polycystic ovary syndrome (PCOS), also known as polyendocrine metabolic ovarian syndrome (PMOS), and obesity before pregnancy. However, current evidence remains insufficient to support their use during pregnancy or breastfeeding, underscoring the importance of careful contraceptive counseling and individualized clinical decision-making. The review emphasizes that nearly half of the clinical recommendations highlight urgent research priorities needed to ensure these therapies can be used as safely and effectively as possible in women of reproductive age.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}